Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12599433 | 0.87 | PIK3CA (0.76) | PIK3CAMTOR | |
| SCHEMBL1899656 | 0.85 | PIK3CA (0.82) | PIK3CAMTOR | |
| SCHEMBL12599143 | 0.84 | PIK3CA (0.47) | PIK3CAMTOR | |
| SCHEMBL8205591 | 0.84 | PIK3CA (0.80) | PIK3CAMTOR | |
| SCHEMBL13439633 | 0.82 | PIK3CA (0.64) | PIK3CAMTOR | |
| SCHEMBL1993484 | 0.82 | PIK3CA (0.82) | PIK3CAMTOR | |
| SCHEMBL13439882 | 0.82 | PIK3CA (0.61) | PIK3CAMTOR | |
| SCHEMBL12599902 | 0.81 | PIK3CA (0.79) | PIK3CAMTOR | |
| SCHEMBL13439636 | 0.80 | PIK3CA (0.43) | PIK3CAMTOR | |
| SCHEMBL15580698 | 0.80 | PIK3CA (0.66) | PIK3CAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7696213-B2 | 4-methylpyridopyrimidinone compounds | PFIZER INC (US) | 2010-04-13 | — | — | US | disclosed |
| US-20080090801-A1 | 4-METHYLPYRIDOPYRIMIDINONE COMPOUNDS | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
| WO-2008021389-A2 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090801-A1 | 4-METHYLPYRIDOPYRIMIDINONE COMPOUNDS | PI4KA, PI4KB, PIK3CA | PIK3CA 3/4885MTOR 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.